ERBB2 and breast neoplasm: Despite significant clinical benefits to trastuzumab in HER2-positive breast tumors, not all patients respond well to this therapy, and therefore experience disease recurrence and progression [44, 45], within a few months of therapy (median of 7.4 months) [8, 13].